|
About Cellectar
Cellectar is a radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers.
Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Our product candidates combine phospholipid ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic doses of radioactivity can be achieved. To date, Cellectar has demonstrated specific uptake and retention of its product candidates in 100% of the 42 tumor types tested in proof-of-principle preclinical animal studies. In addition, three preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate and lung cancer. The compound, originally known as NM404, will be taken through the regulatory process as CLR1404.
Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to "find, treat and follow"” malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way.
Leadership
View the Cellectar leadership team.
Scientific Advisors
View the Cellectar Scientific Advisory Board.
Board of Directors
View the Cellectar Board of Directors.
Key Consultants
View Cellectar's key consultants.
Investor Relations
View information on investing in Cellectar.
Careers
View information regarding careers at Cellectar.
| 
